Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

HKG:1167 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	53.53	155.71	63.52	95.75	152.81
Revenue Growth (YoY)	-65.63%	145.13%	-33.66%	-37.34%	-68.58%
Cost of Revenue	0.59	-	60.32	83.11	139.98
Gross Profit	52.93	155.71	3.2	12.63	12.83
Selling, General & Admin	34.43	43.05	46.62	42.55	44.58
Research & Development	188.59	330.18	372.32	445.65	280.84
Other Operating Expenses	-3.84	-14.33	-3.78	5.36	-20.27
Operating Expenses	219.17	358.89	415.16	493.56	305.14
Operating Income	-166.24	-203.19	-411.95	-480.93	-292.31
Interest Expense	-12.94	-8.4	-8.31	-2.27	-0.57
Interest & Investment Income	31.7	40.86	47.07	24.61	18.77
Earnings From Equity Investments	-0.53	-	-	-	-
Currency Exchange Gain (Loss)	-16.24	12.19	20.69	82.53	-27.26
EBT Excluding Unusual Items	-164.25	-158.53	-352.51	-376.05	-301.38
Gain (Loss) on Sale of Investments	-0.9	-0.02	-7.24	4.19	0.19
Gain (Loss) on Sale of Assets	19.17	-0.14	0.63	-	-
Other Unusual Items	-	2.98	-	-	-
Pretax Income	-145.98	-155.71	-359.12	-371.86	-301.19
Earnings From Continuing Operations	-145.98	-155.71	-359.12	-371.86	-301.19
Net Income	-145.98	-155.71	-359.12	-371.86	-301.19
Net Income to Common	-145.98	-155.71	-359.12	-371.86	-301.19
Shares Outstanding (Basic)	775	775	773	752	747
Shares Outstanding (Diluted)	775	775	773	752	747
Shares Change (YoY)	-0.04%	0.26%	2.79%	0.61%	96.13%
EPS (Basic)	-0.19	-0.20	-0.46	-0.49	-0.40
EPS (Diluted)	-0.19	-0.20	-0.46	-0.49	-0.40
Free Cash Flow	-212.15	-86.21	-402.03	-308.86	-157.6
Free Cash Flow Per Share	-0.27	-0.11	-0.52	-0.41	-0.21
Gross Margin	98.89%	100.00%	5.04%	13.20%	8.40%
Operating Margin	-310.59%	-130.49%	-648.54%	-502.29%	-191.29%
Profit Margin	-272.73%	-100.00%	-565.36%	-388.38%	-197.10%
Free Cash Flow Margin	-396.35%	-55.37%	-632.92%	-322.58%	-103.13%
EBITDA	-153.68	-190.69	-401.12	-473.71	-285.57
EBITDA Margin	-287.12%	-122.47%	-	-	-186.88%
D&A For EBITDA	12.56	12.49	10.83	7.21	6.74
EBIT	-166.24	-203.19	-411.95	-480.93	-292.31
EBIT Margin	-	-130.49%	-	-	-191.29%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.